Expression of DNA topoisomerase II‑α: Clinical significance in laryngeal carcinoma

Feng,Yan; Zhang,Haili; Gao,Wei; Wen,Shuxin; Huangfu,Hui; Sun,Ruifang; Bai,Wei; Wang,Binquan

doi:10.3892/ol.2014.2367

Expression of DNA topoisomerase II‑α: Clinical significance in laryngeal carcinoma

Authors:
- Yan Feng
- Haili Zhang
- Wei Gao
- Shuxin Wen
- Hui Huangfu
- Ruifang Sun
- Wei Bai
- Binquan Wang
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, The First Hospital, Shanxi Medical University, Shanxi, P.R. China, Department of Otolaryngology, Head and Neck Surgery, The First Hospital, Shanxi Medical University, Shanxi, P.R. China, Department of Pathology, Shanxi Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China
Published online on: July 22, 2014 https://doi.org/10.3892/ol.2014.2367
Pages: 1575-1580

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA topoisomerase II‑α (Topo II‑α) is essential for numerous cell processes, including DNA replication, transcription, recombination, and chromosome separation and condensation. Altered Topo II‑α expression may lead to carcinogenesis and cancer progression. The aim of the present study was to investigate the association between Topo II‑α expression levels and clinicopathological data from laryngeal cancer patients. Immunohistochemistry was used to analyze Topo II‑α expression in laryngeal squamous cell carcinoma and distant healthy tissues obtained from 70 patients. In addition, fluorescence in situ hybridization was used to detect Topo II‑α amplification and chromosome 17 ploidy using a laryngeal cancer tissue microarray. The expression of Topo II‑α protein was detected in 71.43% (50/70) of laryngeal carcinoma tissues, in contrast to 9% of healthy tissues (2/22). Furthermore, the expression of Topo II‑α protein was found to be associated with tumor de‑differentiation and advanced tumor T stage. However, the expression of Topo II‑α protein was not identified to be associated with Topo II‑α amplification in laryngeal carcinoma, although was found to positively correlate with chromosome 17 aneuploidy (P<0.05). A higher aneuploidy rate contributed to increased expression levels of Topo II‑α protein. Aberrant Topo II‑α expression and chromosome 17 aneuploidy contributed to the development and progression of laryngeal cancer, indicating that targeting Topo II‑α may provide a treatment strategy for patients with laryngeal cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
2	Ahmad Kiadaliri A, Jarl J, Gavriilidis G and Gerdtham UG: Alcohol drinking cessation and the risk of laryngeal and pharyngeal cancers: a systematic review and meta-analysis. PLoS One. 8:e581582013.
3	Marioni G, Marchese-Ragona R, Cartei G, Marchese F and Staffieri A: Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515. 2006.
4	Licitra L, Bernier J, Grandi C, Locati L, Merlano M, Gatta G and Lefebvre JL: Cancer of the larynx. Crit Rev Oncol Hematol. 47:65–80. 2003.
5	Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:530–542. 1994.
6	Kellner U, Sehested M, Jensen PB, Gieseler F and Rudolph P: Culprit and victim - DNA topoisomerase II. Lancet Oncol. 3:235–243. 2002.
7	Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 9:327–337. 2009.
8	Withoff S, de Vries EG, Keith WN, Nienhuis EF, van der Graaf WT, Uges DR and Mulder NH: Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer. 74:1869–1876. 1996.
9	Bredel M, Slavc I, Birner P, Czech T, Haberler C, Ströbel T, Wolfsberger S, Budka H and Hainfellner JA: DNA topoisomerase IIalpha expression in optic pathway gliomas of childhood. Eur J Cancer. 38:393–400. 2002.
10	Coleman LW, Bronstein IB and Holden JA: Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res. 21:1167–1172. 2001.
11	Monnin KA, Bronstein IB, Gaffney DK and Holden JA: Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol. 30:384–391. 1999.
12	Coleman LW, Perkins SL, Bronstein IB and Holden JA: Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas. Hum Pathol. 31:728–733. 2000.
13	Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U and Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat. 113:457–466. 2009.
14	Gao XH, Yu ZQ, Zhang C, Bai CG, Zheng JM and Fu CG: DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner. Int J Colorectal Dis. 27:429–435. 2012.
15	Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, et al: Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 3:1207–1214. 2004.
16	Lv NL and Kong WM: Expression of multi-drug resistance genes in cervical cancer and its relationship with the effect of concurrent radio-chemotherapy. Zhong Liu Xue Za Zhi. 5:385–388. 2006.(In Chinese).
17	Hicks DG and Tubbs RR: Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol. 36:250–261. 2005.
18	Wong SW, Rangan AM, Bilous AM, Boyages J, Gebski V and Benson EM: The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting. Pathology. 31:90–94. 1999.
19	Horibe Y, Murakami M, Komori K, Imaeda Y and Kasahara M: Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation. APMIS. 108:689–696. 2000.
20	Shvero J, Koren R, Shvili I, Yaniv E, Sadov R and Hadar T: Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables. Am J Clin Pathol. 130:934–939. 2008.
21	Deng G, Yang C and Chen W: The expression of Ki-67 and topoIIalpha in laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 19:396–398. 2005.(In Chinese).
22	Guo YQ: Mdm2 PARP ToPoII in laryngeal carcinoma and its clinical significance. Zhong Guo Yi Yao Dao Kan. 1:112–114. 2011.(In Chinese).